Business
Medicure Acquires Exclusive License to Sell and Market Branded Cardiovascular Drug in the U.S.
Medicure Acquires Exclusive License to Sell and Market Branded Cardiovascular Drug in the ...
About this update from Medicure Inc.
[{"type":"text","content":"\n\n\n\nMedicure Acquires Exclusive License to Sell and Market Branded Cardiovascular Drug in the U.S.\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\n\nCanada NewsWire\nWINNIPEG, Dec. 14, 2017\n\n\n\nWINNIPEG, Dec. 14, 2017 /CNW/ - Medicure Inc. (\"Medicure\" or the \"Company\") (TSXV:MPH, OTC:MCUJF), a pharmaceutical company, today announced that, through its subsidiary, Medicure International Inc., it has acquired, from a large multinational pharmaceutical company, an exclusive license to sell and market a branded cardiovascular drug, for the treatment of patients with primary hyperlipidemia or mixed dyslipidemia, in the United States and its territories.  The licensing agreement is for a term of seven years with extensions to the term available.\n\nThe cardiovascular drug was approved earlier in 2017 by the U.S. Food and Drug Administration (\"FDA\") for sale and marketing in the United States and the Company intends to launch the product using its existing commercial sales force and infrastructure with a target commercial launch date in the first half of 2018. \n\n\"This licensing agreement, similar to our recent licensing of PREXXARTAN®, fits well with Medicure's mission of being a significant cardiovascular pharmaceutical company focused on the U.S. market,\" commented Medicure's President and CEO, Dr. Albert D. Friesen.  \"This will further add to Medicure's revenue in the near term and utilizes the current commercial infrastructure in place for AGGRASTAT® (tirofiban hydrochloride).\"\n\nAbout Medicure Inc.\n\nMedicure is a pharmaceutical company focused on the development and commercialization of therapeutics for the U.S. cardiovascular market. The primary focus of the Company is the marketing and distribution of AGGRASTAT (tirofiban hydrochloride) in the United States, where it is sold through the Company's U.S. subsidiary, Medicure Pharma, Inc. For more information on Medicure please visit www.medicure.com. \n\nNeither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Excha...